Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6198859 | 0.84 | KAT2B (0.80) | KAT2BMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10961239 | 0.83 | KMT2A (0.56) | KAT2BMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27708810 | 0.83 | KAT2B (0.59) | KAT2BMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6200169 | 0.81 | KAT2B (0.81) | KAT2BMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7170020 | 0.81 | KAT2B (0.81) | KAT2BMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10803094 | 0.80 | KAT2B (0.56) | KAT2BMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6198359 | 0.80 | KAT2B (0.78) | KAT2BMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8720672 | 0.80 | KAT2B (0.78) | KAT2BMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11975680 | 0.79 | KAT2B (0.64) | KAT2BMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31473868 | 0.79 | KAT2B (0.43) | KAT2BMAPTRAB9AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673898-B2 | Aminodiazepines as toll-like receptor modulators | ARRAY BIOPHARMA INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673898-B2 | Aminodiazepines as toll-like receptor modulators | ARRAY BIOPHARMA INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20120208801-A1 | Aminodiazepines as Toll-Like Receptor Modulators | ARRAY BIOPHARMA INC. (US) | 2012-08-16 | — | — | US | disclosed |
| EP-1208104-B1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMA (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2004108723-A1 | 4,5-DIHYDRO-IMIDAZO[4,5,1-II]QUINOLIN-6-ONES AS PARP INHIBITORS | ALTANA PHARMA AG (DE) | 2004-12-16 | — | — | WO | disclosed |
| WO-2003103666-A2 | NOVEL 4,5-DIHYDRO-IMIDAZO[4,5,1-IJ]QUINOLIN-6-ONES | ALTANA PHARMA AG (DE) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003051879-A1 | KNOWN AND NOVEL 4,5-DIHYDRO-IMIDAZO[4,5,1-IJ]QUINOLIN-6-ONES USEFUL AS POLY(ADP-RIBOSE)POLYMERASE INHIBITORS | ALTANA PHARMA AG (DE) | 2003-06-26 | — | — | WO | disclosed |
| US-6548494-B1 | 3,4-dihydro-2H-(1,4)diazepino(6,7,1-hi)indol-1-one or 1-thione derivatives where indole C3 could also be N; use treating cancers as well as stroke, head trauma, and neurodegenerative diseases | AGOURON PHARMACEUTICALS, INC. | 2003-04-15 | — | — | US | disclosed |
| CN-1384835-A | Tricycle inhibitors of poly(ADP-ribose) polymerases | AGOURON PHARMA (US) | 2002-12-11 | — | — | CN | disclosed |
| EP-1208104-A2 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMACEUTICALS, INC. (US) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001016136-A2 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
| US-4009994-A | Process and product of optical brightening with quaternized benzofuranyl-benzimidazoles | CIBA-GEIGY CORPORATION (US) | 1977-03-01 | — | — | US | disclosed |
| US-3940417-A | Quaternised benzofuranyl-benzimidazoles | CIBA-GEIGY CORPORATION (US) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208801-A1 | Aminodiazepines as Toll-Like Receptor Modulators | TLR8, TLR1, TLR5 | KAT2B 4034/4885MAPT 2744/4885NPC1 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.